Genetic determinants of response to fibroblast growth factor receptor inhibitors in solid tumours

被引：3
作者：
Leroy, Laura [1 ,2 ]
Cousin, Sophie [2 ]
Italiano, Antoine [1 ,2 ]
机构：
[1] Univ Bordeaux, Bordeaux, France
[2] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 81卷
关键词：
FGFR AMPLIFIED TUMORS; PATIENTS PTS; PHASE-II; AZD4547; CANCER; CHOLANGIOCARCINOMA; MULTICENTER; RESISTANCE; BGJ398;
D O I：
10.1016/j.ejca.2017.04.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 105
页数：4
相关论文
共 13 条
  • [1] Andre F, 2013, CANCER RES, V73, DOI DOI 10.1158/1538-7445.AM2013-LB-145
  • [2] [Anonymous], 2016, ASCO M, DOI DOI 10.1200/jco.2016.34.4_suppl.154
  • [3] [Anonymous], J CLIN ONCOL S
  • [4] Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
    Goyal, Lipika
    Saha, Supriya K.
    Liu, Leah Y.
    Siravegna, Giulia
    Leshchiner, Ignaty
    Ahronian, Leanne G.
    Lennerz, Jochen K.
    Vu, Phuong
    Deshpande, Vikram
    Kambadakone, Avinash
    Mussolin, Benedetta
    Reyes, Stephanie
    Henderson, Laura
    Sun, Jiaoyuan Elisabeth
    Van Seventer, Emily E.
    Gurski, Joseph M., Jr.
    Baltschukat, Sabrina
    Schacher-Engstler, Barbara
    Barys, Louise
    Stamm, Christelle
    Furet, Pascal
    Ryan, David P.
    Stone, James R.
    Iafrate, A. John
    Getz, Gad
    Porta, Diana Graus
    Tiedt, Ralph
    Bardelli, Alberto
    Juric, Dejan
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    Zhu, Andrew X.
    [J]. CANCER DISCOVERY, 2017, 7 (03) : 252 - 263
  • [5] A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.
    Javle, Milind M.
    Shroff, Rachna T.
    Zhu, Andrew
    Sadeghi, Saeed
    Choo, Supin
    Borad, Mitesh J.
    Lowery, Maeve Aine
    El-Khoueiry, Anthony
    Macarulla, Teresa
    Philip, Agop Philip
    Oh, Do-Youn
    Van Cutsem, Eric
    Yeh, Kun-Huei
    Isaacs, Randi
    McGarry, Carolyn
    Sen, Suman
    Bekaii-Saab, Tanios S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
    Kim, S-M
    Kim, H.
    Yun, M. R.
    Kang, H. N.
    Pyo, K-H
    Park, H. J.
    Lee, J. M.
    Choi, H. M.
    Ellinghaus, P.
    Ocker, M.
    Paik, S.
    Kim, H. R.
    Cho, B. C.
    [J]. ONCOGENESIS, 2016, 5 : e241 - e241
  • [7] NOGOVA L, 2014, ASCO M, V32, P8034
  • [8] A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data.
    Paik, Paul K.
    Shen, Ronglai
    Ferry, David
    Soria, Jean-Charles
    Mathewson, Alastair
    Kilgour, Elaine
    Landers, Donal
    Frewer, Paul
    Brooks, Nigel
    Andre, Fabrice
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations
    Pal, Sumanta K.
    Rosenberg, Jonathan E.
    Keam, Bhumsuk
    Wolf, Juergen
    Berger, Raanan
    Dittrich, Christian
    Hoffman-Censits, Jean H.
    Quinn, David
    van der Noll, Ruud
    Burris, Howard A.
    Galsky, Matt D.
    Gravis, Gwenaelle
    Lee, Jae-Lyun
    Medioni, Jacques
    Mortazavi, Amir
    Maroto, Pablo
    Parker, Katie
    Chen, Xueying
    Isaacs, Randi
    Bajorin, Dean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Sequist LV, 2014, AM ASS CANC RES 2014
12